Adamas Pharmaceuticals Shareholder Suit Filed - NASDAQ: ADMS

Adamas Pharmaceuticals Shareholder Suit Filed – NASDAQ: ADMS

//
Posted By
/
Comment0
/
Shareholder Derivative Action Filed Seeking To Remedy Alleged Wrongdoing Committed by Adamas Pharmaceuticals’ Directors and Officers From August 8, 2017 Through September 30, 2019 – Investors of Adamas Pharmaceuticals Encouraged to Contact Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is making investors aware that on April 6, 2020, a verified shareholder derivative complaint was filed in United States District, Northern District of California, seeking to remedy alleged wrongdoing committed by Adamas Pharmaceuticals’ (“Adamas” or the “Company”) (NASDAQ: ADMS) directors and officers from August 8, 2017 through September 30, 2019 (the “Relevant Period”).

According to the shareholder derivative complaint, during the Relevant Period, the Individual Adamas Defendants breached their fiduciary duties by personally making and/or causing the Company to make to the investing public a series of materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the Individual Adamas Defendants willfully or recklessly made and/or allowed certain of the Individual Adamas Defendants to make false and misleading statements to the investing public that failed to disclose, inter alia, that: (1) health insurers and other payors were by and large providing limited or no coverage of GOCOVRI, or were imposing burdensome requirements that limited patients’ access to GOCOVRI; (2) as payors began to indicate their positions on GOCOVRI, the number of physicians prescribing GOCOVRI would decrease precipitously; (3) as a result of the foregoing, GOCOVRI’s sales, market penetration, and market share would be severely impacted in the long run; and (4) the Company failed to maintain internal controls. As a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.

Adamas investors who currently own ADMS shares are encouraged to contact either Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], or John Kehoe, Esq, (215) 792-6676, Ext. 801, [email protected], to discuss the Adamas Pharmaceuticals investigation or potential legal claims.

Kehoe Law Firm, P.C.